Skip to main content
Jiangsu Kanion Pharmaceutical Co.,Ltd. logo

Jiangsu Kanion Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 600557 ISIN · CNE000001CL7 LEI · 300300ZWYT4L0NQ3HS42 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,380 across all filing types
Latest filing 2026-04-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600557

About Jiangsu Kanion Pharmaceutical Co.,Ltd.

https://www.kanion.com/en/

Jiangsu Kanion Pharmaceutical Co.,Ltd. focuses on the research, development, and manufacturing of modern Traditional Chinese Medicine (TCM). The company specializes in therapeutic categories including anti-viral, cardiovascular, gynecological, and pediatric treatments. Key products include Re-Du-Ning Injection and Guizhi Fuling Capsules. Kanion is distinguished by its integration of advanced pharmaceutical technology with traditional herbal medicine, employing intelligent manufacturing systems and standardized extraction processes. Its R&D efforts prioritize the clinical validation and modernization of TCM formulations to address complex health conditions. The company serves a broad market by providing evidence-based botanical therapies developed through rigorous scientific methodology and high-tech production standards.

Recent filings

Filing Released Lang Actions
江苏康缘药业股份有限公司关于收到青参通络颗粒临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Jiangsu Kangyuan Pharmaceutical Co., Ltd. regarding the receipt of a clinical trial approval notice for a drug (Qingshen Tongluo Granules) from the National Medical Products Administration. It details the drug's clinical trial approval, drug development background, market context, and regulatory procedures required before the drug can be marketed. The document is a regulatory announcement about a clinical trial approval and does not contain financial data, earnings, management changes, or other report types. It is a formal disclosure to investors about a regulatory event affecting the company. The document length is 3501 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2026-04-19 Chinese
江苏康缘药业股份有限公司关于聘任副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new vice general manager (副总经理) at Jiangsu Kangyuan Pharmaceutical Co., Ltd. It details the board meeting, the nomination, and the qualifications of the appointee. There is no financial data, no report or presentation, and no mention of voting results or regulatory filings beyond the appointment. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-03-30 Chinese
江苏康缘药业股份有限公司关于收到黑黄赤珠颗粒临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Kangyuan Pharmaceutical Co., Ltd. regarding the receipt of a clinical trial approval notice for a drug named Hei Huang Chi Zhu Granules. It details the drug's clinical trial approval, drug development information, market context, and regulatory procedures ahead. The document is relatively short (2196 characters) and serves as a formal announcement of regulatory approval receipt rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed financial data. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a proxy, voting result, or governance document. The content fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about clinical trial approval and related information, which does not fit other specific categories.
2026-02-25 Chinese
江苏康缘药业股份有限公司关于聘任副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new vice general manager (副总经理) at Jiangsu Kangyuan Pharmaceutical Co., Ltd. It details the board meeting, the appointment decision, and the appointee's background and qualifications. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to shareholder votes or capital changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-02-24 Chinese
江苏康缘药业股份有限公司关于收到运脾化痰通窍颗粒临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Jiangsu Kangyuan Pharmaceutical Co., Ltd. regarding the receipt of a clinical trial approval notice for a new drug from the National Medical Products Administration. It details the drug's clinical trial approval, drug information, market context, and regulatory process. The document is short (1606 characters) and serves as a regulatory announcement about the approval to start clinical trials, not a financial report or detailed study. It does not contain financial statements, earnings data, or management discussion. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about clinical trial approval and related information that does not fit other specific categories.
2026-01-26 Chinese
江苏康缘药业股份有限公司关于收到车前子片临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Kangyuan Pharmaceutical Co., Ltd. regarding the receipt of a clinical trial approval notice for a drug (Cheqianzi Pian) from the National Medical Products Administration. It details the drug's clinical trial approval, research background, market situation, and regulatory steps required before the drug can be marketed. The document is a regulatory announcement about a clinical trial approval, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed financial performance information. It is a regulatory filing informing the market about a material event related to drug development and regulatory approval. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short (1802 characters), and it is not a report publication announcement or certification letter, so RNS fits best.
2026-01-20 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.